• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BOSTON SCIENTIFIC CORPORATION STERLING; CATHETER, PERCUTANEOUS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BOSTON SCIENTIFIC CORPORATION STERLING; CATHETER, PERCUTANEOUS Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Vascular Dissection (3160)
Event Date 09/23/2022
Event Type  Injury  
Manufacturer Narrative
A1 - patient identifier: (b)(6).A2 - age at time of event: 61 years old at the time of enrollment.
 
Event Description
Elegance clinical trial: it was reported that vessel dissection occurred.The subject underwent treatment with the sterling balloon on (b)(6) 2022 as a part of the elegance clinical trial.The target lesion #001 was in the right proximal superficial femoral artery, right mid superficial femoral artery extending into right distal superficial femoral artery with 6 mm proximal reference vessel diameter and 6 mm distal reference vessel diameter with lesion length of 280 mm and 30% stenosis and was classified as transatlantic intersociety consensus (tasc) ii c lesion.Prior to target lesion treatment, the pre-treatment dilation was performed using 5 mm x 150 sterling pta balloon.Treatment of target lesion was performed by using 6 mmx 200 mm ranger drug coated balloon and implanting 6 mm x 120 mm and 6 mm x 80 mm eluvia drug eluting stents.Post treatment, 6 mm x 200 mm ranger drug coated balloon was used for post dilation and the final residual stenosis was noted to be 10%.On (b)(6) 2022, on the same day of index procedure, during the treatment of target lesion #001, dissection of grade c was noted.It was confirmed that dissection was due to 5 mm x 150 mm sterling pta balloon.In response to the event, bailout stent was placed.Post treatment, the final residual stenosis the target lesions were noted to be 10%.On the same day, the event was considered resolved and the subject was discharged on aspirin and clopidogrel.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
STERLING
Type of Device
CATHETER, PERCUTANEOUS
Manufacturer (Section D)
BOSTON SCIENTIFIC CORPORATION
300 boston scientific way
marlborough MA 01752
Manufacturer (Section G)
BOSTON SCIENTIFIC SCIMED, INC
two scimed place
maple grove
Manufacturer Contact
rachel shields
4100 hamline ave n
arden hills, MN 55112
6512422111
MDR Report Key18879381
MDR Text Key337404308
Report Number2124215-2024-11295
Device Sequence Number1
Product Code LIT
Combination Product (y/n)N
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Study,Health Professional,Company Representative
Reporter Occupation Physician
Type of Report Initial
Report Date 03/11/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/11/2024
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received02/14/2024
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient SexFemale
Patient RaceWhite
-
-